
Ross Givens
Chief Market Strategist
Ross Givens is a veteran trader with over 15 years of experience and a former VP at a major Wall Street investment bank. Specializing in small-cap stocks and momentum-driven plays, Ross identifies high-probability setups before they hit the mainstream. As Lead Strategist at Traders Agency, he has guided hundreds of successful trades and developed multiple flagship publications.

Breakouts Amid the Chop
The S&P 500 has gone nowhere for nearly two months now. But beneath the surface – it’s a completely different story.

SpaceX Will Be $500 One Day… But First It Could Hit $50 (Here's WHY)
SpaceX stock price prediction: why unlocks could send shares to $50 before a run past $500. Here's the supply-demand math behind the call.

The Next Rotation is Already Underway
The major indexes look quiet. But one signal suggests the real story may be developing somewhere far less obvious.

China Is Preparing For $38,000 Gold… And Nobody Is Talking About It
China's gold stockpile strategy hints at a dollar shift toward $38,000 gold. See why Beijing and Washington are quietly repositioning now.

The Smart Money is Moving FAST
Something unusual is happening inside the portfolios of the market’s biggest players – and it could reshape what leads next.

NVIDIA's Next Big Bet Isn't AI… It's Physical AI
Nvidia investments shift toward humanoid robots as one pure-play stock emerges. See why smart money is targeting physical AI now.

Confusing Money Flows
Money flows have been violently rotating over the past 12 months – all in one confusing mess. How can any trader spot the opportunity within?

The FDA Just Approved This $1 Stock… Analysts See 150% Upside
See why this FDA just approved stock list pick, Stereotaxis (STXS), trades at $1.65 with analysts eyeing 150% upside after key approvals.

Still Clinging on to This Crowded Trade?
Momentum is fading in this hot sector. But traders may still be crowding into this trade. Are you?

I Found 5 Stocks About to Enter Their Most Explosive Phase
5 stocks at the exact Stage 2 breakout point. Learn how to find stocks before they surge using Stan Weinstein's stage analysis method.

Huge Source of Market Confusion
Why has the stock market been so confusing lately? It all has to do with one little-known market effect that has reached its highest levels in yeas. Ross investigates.

How to Buy Anthropic Before the IPO at a 32% Discount
Can I invest in Anthropic before IPO? DXYZ offers pre-IPO exposure at a 32% discount to NAV—here's the trade setup and hedge.
Stop watching.
Start winning.
50,000+ traders get our daily brief before the market opens.
You're subscribed!
Check your inbox.
Free. No spam. Unsubscribe anytime.
